Search results for "Autoantibodies"

showing 10 items of 292 documents

Antibodies against Lewis antigens inhibit the binding of human norovirus GII.4 virus-like particles to saliva but not to intestinal Caco-2 cells.

2016

BACKGROUND: Human noroviruses (NoVs) are the main cause of gastroenteritis worldwide. The most commonly detected NoV strains belong to the genetically diverse GII.4 genotype, with new pandemic variants emerging periodically. Despite extensive efforts, NoV investigation has been hampered by the lack of an effective in vitro cell culture system. However, NoV-derived recombinant virus-like particles (VLPs) resembling empty capsids are good surrogates for analysing NoV antigenicity and virus-ligand interactions. NoV VLPs have been reported to bind to histo-blood group antigens (HBGAs). We have analysed the ability of NoV VLPs derived from GI.1 genotype and from three GII.4 genotype variants, GI…

0301 basic medicineAdultMaleSalivaAntigenicitymedicine.drug_classSwinevirusesVirus AttachmentMonoclonal antibodyImmunofluorescenceVirusMicrobiology03 medical and health sciencesLewis Blood Group Antigensfluids and secretionsAntigenstomatognathic systemGII.4 genotypeHisto-blood group antigens (HBGAs)VirologymedicineAnimalsHumansChildSalivaAutoantibodiesbiologymedicine.diagnostic_testResearchMucinNorovirusvirus diseasesEpithelial CellsMiddle AgedVirology3. Good healthVirus-like particles (VLPs)030104 developmental biologyInfectious DiseasesHuman norovirus (NoV)Host-Pathogen Interactionsbiology.proteinReceptors VirusReceptor bindingFemaleAntibodyCaco-2 Cells
researchProduct

Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.

2017

Objective:To identify cell-surface antibodies in patients with neuromyotonia and to describe the main clinical implications.Methods:Sera of 3 patients with thymoma-associated neuromyotonia and myasthenia gravis were used to immunoprecipitate and characterize neuronal cell-surface antigens using reported techniques. The clinical significance of antibodies against precipitated proteins was assessed with sera of 98 patients (neuromyotonia 46, myasthenia gravis 52, thymoma 42; 33 of them with overlapping syndromes) and 219 controls (other neurologic diseases, cancer, and healthy volunteers).Results:Immunoprecipitation studies identified 3 targets, including the Netrin-1 receptors DCC (deleted i…

0301 basic medicineAdultMaleThymomaNeuromyotoniaDeleted in Colorectal CancerThymomaCell Adhesion Molecules NeuronalNerve Tissue ProteinsReceptors Cell SurfaceTransfectionArticle03 medical and health sciences0302 clinical medicineAntigenMyasthenia GravismedicineHumansImmunoprecipitationNerve Growth FactorsReceptorMuscle SkeletalNeural Cell Adhesion MoleculesAgedAutoantibodiesbiologybusiness.industryElectromyographyTumor Suppressor ProteinsCalcium-Binding ProteinsAutoantibodyMembrane ProteinsThymus NeoplasmsMiddle AgedNetrin-1medicine.diseaseDCC ReceptorMagnetic Resonance ImagingMyasthenia gravis030104 developmental biologyHEK293 CellsImmunologybiology.proteinFemaleNeurology (clinical)AntibodybusinessNetrin Receptors030217 neurology & neurosurgeryNeurology
researchProduct

Secretion of autoimmune antibodies in the human subcutaneous adipose tissue

2018

The adipose tissue (AT) contributes to systemic and B cell intrinsic inflammation, reduced B cell responses and secretion of autoimmune antibodies. In this study we show that adipocytes in the human obese subcutaneous AT (SAT) secrete several pro-inflammatory cytokines and chemokines, which contribute to the establishment and maintenance of local and systemic inflammation, and consequent suboptimal immune responses in obese individuals, as we have previously shown. We also show that pro-inflammatory chemokines recruit immune cells expressing the corresponding receptors to the SAT, where they also contribute to local and systemic inflammation, secreting additional pro-inflammatory mediators.…

0301 basic medicineB CellsPhysiologylcsh:MedicineAutoimmunityPathology and Laboratory MedicineSystemic inflammationWhite Blood CellsAnimal CellsImmune PhysiologyPlasma cell differentiationAdipocytesMedicine and Health Scienceslcsh:ScienceImmune ResponseConnective Tissue CellsInnate Immune SystemMultidisciplinaryT CellsBody Fluids3. Good healthBloodmedicine.anatomical_structurePhysiological ParametersConnective TissueCytokinesChemokinesCellular TypesAnatomymedicine.symptomResearch ArticleLipolysisImmune CellsImmunologySubcutaneous FatInflammationBiology03 medical and health sciencesSigns and SymptomsImmune systemAntigenDiagnostic MedicinemedicineHumansObesityAntibody-Producing CellsB cellAutoantibodiesInflammationBlood CellsTumor Necrosis Factor-alphalcsh:RBody WeightAutoantibodyBiology and Life SciencesGerminal centerCell BiologyMolecular DevelopmentOxidative StressBiological Tissue030104 developmental biologyImmune SystemImmunologylcsh:QTranscription FactorsDevelopmental BiologyPLOS ONE
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephal…

2019

N-Methyl-D-aspartate (NMDA) receptors (NMDARs) are among the most important excitatory neurotransmitter receptors in the human brain. Autoantibodies to the human NMDAR cause the most frequent form of autoimmune encephalitis involving autoantibody-mediated receptor cross-linking and subsequent internalization of the antibody-receptor complex. This has been deemed to represent the predominant antibody effector mechanism depleting the NMDAR from the synaptic and extra-synaptic neuronal cell membrane. To assess in detail the molecular mechanisms of autoantibody-induced NMDAR endocytosis, vesicular trafficking, and exocytosis we transiently co-expressed rat GluN1-1a-EGFP and GluN2B-ECFP alone or…

0301 basic medicineEndosomeautoantibodiesmedia_common.quotation_subjectN-Methyl-D-aspartate receptorsEndocytosisExocytosislcsh:RC346-42903 medical and health sciences0302 clinical medicineNeurotransmitter receptorendocytosisInternalizationReceptorlcsh:Neurology. Diseases of the nervous systemmedia_commonOriginal ResearchChemistryAutoantibodyautoimmune encephalitisCell biology030104 developmental biologynervous systemNeurologyRabNeurology (clinical)exocytosisvesicular trafficking030217 neurology & neurosurgerycross-linkingFrontiers in neurology
researchProduct

T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita

2016

AbstractT cells are key players in autoimmune diseases by supporting the production of autoantibodies. However, their contribution to the effector phase of antibody-mediated autoimmune dermatoses, i.e., tissue injury and inflammation of the skin, has not been investigated. In this paper, we demonstrate that T cells amplify the development of autoantibody-induced tissue injury in a prototypical, organ-specific autoimmune disease, namely epidermolysis bullosa acquisita (EBA) – characterized and caused by autoantibodies targeting type VII collagen. Specifically, we show that immune complex (IC)-induced inflammation depends on the presence of T cells – a process facilitated by T cell receptor (…

0301 basic medicineEpidermolysis bullosa acquisitamedicine.medical_specialtyCollagen Type VIINeutrophilsT-LymphocytesGene ExpressionMice NudeInflammationAntigen-Antibody ComplexCell CommunicationEpidermolysis Bullosa AcquisitaArticleMice03 medical and health sciencesCricetulus0302 clinical medicinemedicineAnimalsHumansAutoantibodiesSkinAutoimmune diseaseMice Inbred BALB CMultidisciplinarybusiness.industryT-cell receptorAutoantibodyAntibodies MonoclonalReceptors Antigen T-Cell gamma-deltamedicine.diseaseNatural killer T cellDermatologyImmune complexMice Inbred C57BLDisease Models Animal030104 developmental biologyLymphatic systemImmunoglobulin GImmunologyNatural Killer T-CellsLymph NodesRabbitsmedicine.symptombusinessSpleenSignal Transduction030215 immunologyScientific Reports
researchProduct

Autoimmune aspects in glaucoma

2016

The pathogenesis of glaucoma, a common neurodegenerative disease, involves an immunologic component. Studies demonstrate changes of autoantibody concentrations against retinal and optic nerve head antigens in glaucoma patients. Furthermore we found antibody deposits in human glaucomatous retinae in a pro-inflammatory environment. Clinical studies showed up regulated, but also significantly down-regulated autoantibody levels. These antibodies belong to the natural autoimmunity. The upregulation of autoantibodies can be associated with fatal conditions, but several studies demonstrate that natural autoantibodies entail also neuroprotective characteristics and influence the protein expression …

0301 basic medicineGlaucomaAutoimmunityDiseasemedicine.disease_causeNeuroprotectionAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicineAntigenmedicineAnimalsHumansAutoantibodiesPharmacologybusiness.industryAutoantibodyGlaucomamedicine.diseaseNeuroprotection030104 developmental biologyImmunology030221 ophthalmology & optometryBiomarker (medicine)sense organsbusinessEuropean Journal of Pharmacology
researchProduct

Early inflammatory players in cutanous fibrosis.

2017

Systemic sclerosis (SSc) is one of the most complex systemic autoimmune diseases with multi-organ involvement and heterogeneous clinical manifestations. The exact etiology of SSc is still unknown. However, identified target structures are components of endothelial cells, the innate/adaptive immune systems and fibroblasts, resulting in the hallmarks of the disease in form of inflammation/autoimmunity, vasculopathy and fibrosis of the skin and internal organs. There has been a large body of evidence that the adaptive immune system with autoreactive T and B cells producing autoantibodies plays a central role in the pathogenesis of SSc but the role of earlier pathogenic processes involving the …

0301 basic medicineInflammationAutoimmunityDermatologyBiologymedicine.disease_causeBiochemistryAutoimmunity03 medical and health sciences0302 clinical medicineImmune systemmedicineLeukocytesHumansPlatelet activationskin and connective tissue diseasesMolecular BiologyAutoantibodiesSkinAutoimmune diseaseInflammationImmunity CellularInnate immune systemScleroderma Systemicintegumentary systemInnate lymphoid cellEndothelial CellsFibroblastsmedicine.diseaseAcquired immune systemPlatelet ActivationFibrosisImmunity Innate030104 developmental biology030220 oncology & carcinogenesisImmunologymedicine.symptomImmunosuppressive AgentsJournal of dermatological science
researchProduct

Decreased proportions of CD4 + IL17+/CD4 + CD25 + CD127- and CD4 + IL17+/CD4 + CD25 + CD127 - FoxP3+ T cells in children with autoimmune thyroid dise…

2016

Until now, altered balance of Th1 and Th2 immune cells has been postulated to play an important role in the pathogenesis of autoimmune thyroid diseases (AITD). However, recent studies on thyroid diseases have suggested a new role for Th17 cells that have been classified as a new lineage, distinct from Th1, Th2 and Treg cells. Despite wide interest, the role of Th17 cells in the pathogenesis of inflammatory and autoimmune diseases is still debated. The aim of the study was to estimate the proportions of Th17/Treg T cells in peripheral blood from patients with Graves' disease (GD; n = 29, mean age 15.4 ± 5.1 years), Hashimoto's thyroiditis (HT; n = 39, mean age 15.2 ± 4.1 years) and in health…

0301 basic medicineMaleAdolescentGraves' diseaseT cellImmunologychemical and pharmacologic phenomenaHashimoto DiseaseT-Lymphocytes RegulatoryThyroiditisAutoimmune DiseasesImmunophenotyping03 medical and health sciencesYoung Adult0302 clinical medicineImmune systemT-Lymphocyte SubsetsmedicineImmunology and AllergyHumansHashimoto DiseaseLymphocyte CountChildAutoantibodiesbusiness.industryThyroidFOXP3hemic and immune systemsmedicine.diseaseThyroid DiseasesAnti-thyroid autoantibodiesGraves Disease030104 developmental biologymedicine.anatomical_structurePhenotypeCase-Control StudiesImmunologyTh17 CellsFemalebusinessBiomarkers030215 immunologyAutoimmunity
researchProduct

Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT.

2015

Objective To quantify clinical outcome in patients with steroid-responsive encephalopathy and associated autoimmune thyroiditis (SREAT) after the acute phase and explore potential associations of initial serum thyroid peroxidase antibody titers (TPO-Abs) with outcome. Materials and methods Retrospective chart review of patients diagnosed with SREAT between 01/2005 and 05/2014 in a tertiary care center and followed in an affiliated autoimmune outpatient clinic. Outcome was quantified using the extended Glasgow Outcome Scale (GOS-E). We calculated Pearson's correlation coefficients to quantify associations with clinical outcome at follow-up. Results Among 134 patients with encephalopathy of u…

0301 basic medicineMaleAnti-Inflammatory AgentsGlasgow Outcome Scaleblood [Iodide Peroxidase]0302 clinical medicineblood [Hashimoto Disease]blood [Encephalitis]Outpatient clinicHashimoto Diseasebiologytherapy [Hashimoto Disease]Glasgow Outcome Scaletherapy [Encephalitis]therapeutic use [Anti-Inflammatory Agents]General MedicineMiddle Agedblood [Thyroiditis Autoimmune]Magnetic Resonance Imagingtherapy [Thyroiditis Autoimmune]Treatment OutcomeNeurologyEncephalitisFemaleSteroidsImmunosuppressive AgentsAdultmedicine.medical_specialtyEncephalopathyHashimoto DiseaseIodide PeroxidaseAutoimmune thyroiditisanalysis [Autoantibodies]03 medical and health sciencesimmunology [Thyroiditis Autoimmune]Thyroid peroxidaseInternal medicinemedicineHumansddc:610immunology [Encephalitis]therapeutic use [Steroids]AgedAutoantibodiesRetrospective Studiesbusiness.industrytherapeutic use [Methotrexate]Thyroiditis AutoimmuneRetrospective cohort studymedicine.diseasetherapeutic use [Immunosuppressive Agents]immunology [Hashimoto Disease]030104 developmental biologyMethotrexateImmunologybiology.proteinEtiologyNeurology (clinical)businessimmunology [Iodide Peroxidase]030217 neurology & neurosurgeryFollow-Up StudiesActa neurologica Scandinavica
researchProduct